Why the study?
Early recurrence after an acute stroke event in AF presents a therapeutic challenge balancing ischemic prevention with hemorrhagic risk, motivating quantification of its incidence and predictors.
Does anticoagulation therapy reduce early stroke recurrence in patients with atrial fibrillation after a first-ever acute stroke event?
Cohort (n=1,795)
No
Does anticoagulation therapy reduce early stroke recurrence in patients with atrial fibrillation after a first-ever acute stroke event?
Early stroke recurrence in patients with atrial fibrillation occurs predominantly within the first 30 days and is largely ischemic, with DOAC therapy significantly reducing this risk.
Hypothesis-generating for ER predictors in post-stroke AF; prospective trials needed before guiding anticoagulation timing.
Introduction: Early recurrence (ER) after an acute stroke event (ASE; ischemic or hemorrhagic) in patients with atrial fibrillation (AF) presents a therapeutic challenge due to the need to balance ischemic prevention with hemorrhagic risk. This study aimed to quantify ER incidence, both ischemic and hemorrhagic, and identify its predictors using real-world data from a prospective registry. Patients and methods: Retrospective analysis of patients with AF, either known or detected within 6 months, who were admitted for a first-ever ASE to a tertiary stroke center between 2005 and 2024. ER was defined as any recurrent event within 6 months. Baseline characteristics, CHA 2 DS 2 -VASc score, CHADS-VA score, stroke severity, anticoagulation type, AF detection timing, and monitoring duration were recorded. Cox and Fine-Gray models identified independent predictors. Results: Among 1795 patients, 108 (6.0%) experienced ER. The cumulative incidence was 6.3% (95% CI 5.1–7.4), and most events occurred within the first 30 days. Independent predictors included higher CHA 2 DS 2 -VASc score (sHR = 1.252, p = 0.023), lower initial stroke severity (sHR = 0.918, p < 0.001), concomitant stroke etiologies (sHR = 2.008, p = 0.001), and AF detected within 30 days after stroke (sHR = 1.644, p = 0.026). DOAC use was protective (sHR = 0.484, p = 0.003), while VKA showed a non-significant trend (sHR = 0.637, p = 0.068). Interaction analysis showed increased recurrence risk only in non-anticoagulated patients with AF detected after stroke. These findings were consistent across sensitivity analyses restricted to ischemic stroke, incorporating time-dependent anticoagulation, or comparing CHADS-VA and CHA 2 DS 2 -VASc scores. Conclusions: ER, predominantly ischemic, occurred mainly within 30 days. Risk factors included AF detection timing, CHA 2 DS 2 -VASc score, stroke severity, concomitant causes, and anticoagulation status, supporting early risk stratification and DOAC initiation.
No takes yet. Share an insight, caveat, or question.
Guisado‐Alonso et al. (2025) conducted a cohort in Atrial fibrillation with acute stroke event (n=1,795). Direct oral anticoagulants (DOAC) vs. No anticoagulation was evaluated on Early stroke recurrence (ischemic or hemorrhagic) within 6 months (sHR 0.484, 95% CI 0.298-0.786, p=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: